论文部分内容阅读
目的:探讨阿托伐他片汀治疗急性冠脉综合征(ACS)的临床疗效。方法:选择2013年3月至2013年12月我院收治的156例ACS患者,按随机字数表法分为实验组和对照组各78例,两组均采取常规治疗,实验组在此基础上加用阿托伐他汀钙片,对照组则用辛伐他汀滴丸。对比两组治疗效果及心血管事件发生率。结果:两组治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、血清高敏C反应蛋白(hs-CRP)、纤维蛋白原(Fg)和尿酸水平均明显下降,且实验组下降更明显,比较差异均有统计学意义(P<0.05);治疗期间实验组心血管事件发生率率为8.97%(7/78),显著低于对照组的24.36%(19/78),比较差异均有统计学意义(P<0.05)。结论:阿托伐他汀片治疗ACS的临床效果优于辛伐他汀滴丸,能有效降低心血管事件的发生,值得的临床推广。
Objective: To investigate the clinical efficacy of atorvastatin in the treatment of acute coronary syndrome (ACS). Methods: A total of 156 ACS patients admitted to our hospital from March 2013 to December 2013 were randomly divided into experimental group and control group, 78 cases in each group. Both groups were treated by conventional therapy. On the basis of the experimental group Add atorvastatin calcium tablets, the control group was simvastatin dropping pills. The therapeutic effects and the incidence of cardiovascular events were compared between the two groups. Results: The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), serum hs-CRP, fibrinogen (Fg) and uric acid (P <0.05). The incidence of cardiovascular events was 8.97% (7/78) in the experimental group during treatment, which was significantly lower than that of the control group (24.36) % (19/78), the difference was statistically significant (P <0.05). Conclusion: The clinical effect of atorvastatin tablets on ACS is better than simvastatin drip pills, which can effectively reduce the occurrence of cardiovascular events and is worthy of clinical promotion.